Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1225 of 2026 entries
View as:

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02731313 Org: User:
Start: 07/31/12 End: 10/31/14 Due: 10/31/15

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03221179 Org: User:
Start: 07/10/17 End: 07/05/19 Due: 07/05/20

An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT01893268 Org: User:
Start: 07/25/13 End: 03/20/18 Due: 03/20/19

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

Phase: N/A Priority: Normal
NCT ID: NCT02604836 Org: User:
Start: 06/30/04 End: 04/30/06 Due: 04/30/07

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03380780 Org: User:
Start: 03/12/18 End: 09/18/18 Due: 09/18/19

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01591460 Org: User:
Start: 08/31/12 End: 06/30/14 Due: 06/30/15

A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT02550873 Org: User:
Start: 09/01/15 End: 05/02/17 Due: 05/02/18

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01590719 Org: User:
Start: 07/31/12 End: 10/31/14 Due: 10/31/15

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01723878 Org: User:
Start: 12/30/13 End: 06/20/17 Due: 06/20/18

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Phase: N/A Priority: Normal
NCT ID: NCT04548999 Org: User:
Start: 12/03/20 End: 03/08/29 Due: 03/08/30

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Phase: N/A Priority: Normal
NCT ID: NCT04557150 Org: User:
Start: 11/11/20 End: 02/20/26 Due: 02/20/27

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Phase: N/A Priority: Normal
NCT ID: NCT00107653 Org: User:
Start: 10/31/04 End: 09/30/07 Due: 09/30/08

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03037385 Org: User:
Start: 03/17/17 End: 03/21/24 Due: 03/21/25

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT04035005 Org: User:
Start: 08/12/19 End: 01/19/28 Due: 01/19/29

SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

Phase: N/A Priority: Normal
NCT ID: NCT00412334 Org: User:
Start: 01/31/07 End: 09/30/10 Due: 09/30/11

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT06065748 Org: User:
Start: 12/11/23 End: 12/30/28 Due: 12/30/29

Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223

Phase: N/A Priority: Normal
NCT ID: NCT02383576 Org: User:
Start: 04/30/15 End: 01/22/16 Due: 01/22/17

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Phase: N/A Priority: Normal
NCT ID: NCT02118584 Org: User:
Start: 09/15/14 End: 10/05/23 Due: 10/05/24

A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04605718 Org: User:
Start: 12/07/20 End: 03/09/23 Due: 03/09/24

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02242942 Org: User:
Start: 12/31/14 End: 08/31/25 Due: 08/31/26

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04303858 Org: User:
Start: 05/04/20 End: 08/15/26 Due: 08/15/27

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

Phase: N/A Priority: Normal
NCT ID: NCT02762383 Org: User:
Start: 03/31/05 End: 06/30/09 Due: 06/30/10

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

Phase: N/A Priority: Normal
NCT ID: NCT02761629 Org: User:
Start: 04/30/05 End: 05/31/08 Due: 05/31/09

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT02291289 Org: User:
Start: 04/17/15 End: 03/24/21 Due: 03/24/22

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05686551 Org: User:
Start: 02/03/23 End: 04/01/27 Due: 04/01/28